Impact of adjuvant gemcitabine containing chemotherapy following radical nephroureterectomy for patients with upper tract urothelial carcinoma: Results from a propensity-score matched cohort study

Basit Öğe Kaydı
dc.authorid0000-0002-6308-1763
dc.authorid0000-0003-0906-4417
dc.contributor.authorHongda, Zhao
dc.contributor.authorKang, Liu
dc.contributor.authorNg, Chi-Fai
dc.contributor.authorde la Rosette, Jean J. M. C. H.
dc.contributor.authordel Pilar Laguna Pes, Maria
dc.contributor.authorGontero, Paolo
dc.contributor.authorBaard, Joyce
dc.contributor.authorYıldız, Özcan
dc.contributor.authorTeoh, Jeremy Yuen-Chun
dc.date.accessioned2023-10-30T06:16:15Z
dc.date.available2023-10-30T06:16:15Z
dc.date.issued2023
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.departmentİstanbul Medipol Üniversitesi, Uluslararası Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Üroloji Ana Bilim Dalı
dc.description.abstractBACKGROUND: The evidence regarding perioperative adjuvant chemotherapy and personalized surveillance strategies for upper tract urothelial carcinoma is limited. OBJECTIVE: To evaluate whether adjuvant gemcitabine containing chemotherapy affects the oncological outcomes of advanced upper tract urothelial carcinoma (UTUC). METHODS: The CROES-UTUC registry is an observational, international, multi-center study on patients diagnosed with UTUC. Patient and disease characteristics from 2380 patients with UTUC were collected, and finally 738 patients were included in this analysis. The primary outcome of this study was recurrence-free survival. Propensity score matching was performed. Kaplan-Meier and multivariate Cox regression analyses were performed by stratifying patients according to the treatment of adjuvant chemotherapy. RESULTS: A total of 738 patients were included in this analysis, and 59 patients received adjuvant chemotherapy (AC), including 50 patients who received gemcitabine. A propensity score matching was performed, including 50 patients who received gemcitabine containing treatment and 50 patients without adjuvant chemotherapy. Disease recurrence occurred in 34.0% of patients. The recurrence rate in the AC group was 22.0%, which was significantly lower than the non-AC group (46.0%). Kaplan-Meier analyses also showed that AC was associated with a lower likelihood of tumor recurrence (p = 0.047). However, AC was not significantly associated with a higher overall survival (OS) (p = 0.908) and cancer-specific survival (CSS) (p = 0.979). Upon multivariate Cox regression analysis, AC was associated with a lower risk of tumor recurrence (HR = 0.297, p = 0.028). CONCLUSION: The present study confirms that adjuvant gemcitabine containing chemotherapy could decrease the risk of tumor recurrence in patients with locally advanced UTUC following nephroureterectomy. However, more studies are need to draw a clearer image of the value of this treatment method.
dc.description.sponsorshipSTORZ to the Clinical Research Office of the Endourology Society (CROES)en_US
dc.identifier.citationHongda, Z., Kang, L., Ng, C., de la Rosette, J. J. M. C. H., del Pilar Laguna Pes, M., Gontero, P. ... Teoh, J. Y. (2023). Impact of adjuvant gemcitabine containing chemotherapy following radical nephroureterectomy for patients with upper tract urothelial carcinoma: Results from a propensity-score matched cohort study. Bladder Cancer, 9(3), 217-226. https://dx.doi.org/10.3233/BLC-230041
dc.identifier.doi10.3233/BLC-230041
dc.identifier.endpage226
dc.identifier.issn2352-3727
dc.identifier.issn2352-3735
dc.identifier.issue3
dc.identifier.pmid38993186
dc.identifier.scopus2-s2.0-85174039377
dc.identifier.scopusqualityQ2
dc.identifier.startpage217
dc.identifier.urihttps://dx.doi.org/10.3233/BLC-230041
dc.identifier.urihttps://hdl.handle.net/20.500.12511/11660
dc.identifier.volume9
dc.identifier.wos001079389600003en_US
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorde la Rosette, Jean J. M. C. H.
dc.institutionauthordel Pilar Laguna Pes, Maria
dc.institutionauthorYıldız, Özcan
dc.language.isoen
dc.publisherIOS Press BV
dc.relation.ispartofBladder Canceren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsAttribution-NonCommercial 4.0 International*
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/*
dc.subjectAdjuvant Chemotherapy
dc.subjectGemcitabine
dc.subjectOutcome Assessment
dc.subjectUrothelial Carcinoma
dc.subjectNephroureterectomy
dc.titleImpact of adjuvant gemcitabine containing chemotherapy following radical nephroureterectomy for patients with upper tract urothelial carcinoma: Results from a propensity-score matched cohort study
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Rosettee-Jean-2023.pdf
Boyut:
660.34 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu